Compare WD & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WD | TNDM |
|---|---|---|
| Founded | 1937 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2010 | 2013 |
| Metric | WD | TNDM |
|---|---|---|
| Price | $38.15 | $20.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 25 |
| Target Price | ★ $49.33 | $26.90 |
| AVG Volume (30 Days) | 501.3K | ★ 2.4M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 7.04% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,234,306,000.00 | $1,014,736,000.00 |
| Revenue This Year | $5.82 | $6.14 |
| Revenue Next Year | $8.84 | $8.10 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.99 | 7.93 |
| 52 Week Low | $31.40 | $12.26 |
| 52 Week High | $66.47 | $29.65 |
| Indicator | WD | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 55.12 | 59.52 |
| Support Level | $31.40 | $17.61 |
| Resistance Level | $52.37 | $20.44 |
| Average True Range (ATR) | 1.65 | 1.34 |
| MACD | 0.44 | 0.08 |
| Stochastic Oscillator | 56.63 | 94.80 |
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of its total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.